Identifying Cancer Genes in in Blood and Bone Marrow Samples From Patients With Acute Myeloid Leukemia
NCT00897182 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 96
Last updated 2016-07-04
Summary
RATIONALE: Studying samples of blood and bone marrow in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify genes related to cancer. It may also help doctors diagnose cancer and predict how patients will respond to treatment.
PURPOSE: This research study is identifying cancer-related genes in blood and/or bone marrow samples from patients with acute myeloid leukemia.
Conditions
Interventions
- GENETIC
-
microarray analysis
- GENETIC
-
polymerase chain reaction
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
Alliance for Clinical Trials in Oncology
lead OTHER
Principal Investigators
-
Janet Rowley, MD · University of Chicago
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2014-03-31
- Completion
- 2014-03-31
Countries
- United States
Study Locations
More Related Trials
-
Cytogenetic Studies in Acute Leukemia and Multiple Myeloma
NCT00048958 ·Status: ACTIVE_NOT_RECRUITING
-
S0106B Studying Bone Marrow Samples From Women With Acute Myeloid Leukemia
NCT01575535 ·Status: COMPLETED
-
Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia
NCT01245231 ·Status: COMPLETED
-
Biomarkers in Blood Samples From Patients With Acute Myeloid Leukemia
NCT01385150 ·Status: COMPLETED
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia
NCT02581917 ·Status: COMPLETED
-
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
NCT01076569 ·Status: COMPLETED
-
Prognostic Values of Next Generation Sequencing (NGS) in Acute Myeloid Leukemia Patients With Allo-HSCT
NCT03715621 ·Status: UNKNOWN
-
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
NCT02756962 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Molecular Characterization of Patients With Acute Myeloid Leukemia and the Impact of Clonal Evolution in the Response to Therapeutic Treatments
NCT06764459 ·Status: RECRUITING
-
Biomarkers in Predicting Response to Treatment in Bone Marrow Samples From Young Patients With Acute Myeloid Leukemia
NCT01321385 ·Status: COMPLETED
-
Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML)
NCT04920188 ·Status: TERMINATED
-
Biomarkers in Bone Marrow and Blood Samples From Older Patients With Acute Myeloid Leukemia Treated With Cytarabine-Based Therapy
NCT01169363 ·Status: COMPLETED
-
Studying Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01581528 ·Status: COMPLETED
-
Study of Gemtuzumab Ozogamicin Therapy in DNA Samples From Patients With Acute Myeloid Leukemia Treated on COG-AAML0531
NCT01407757 ·Status: COMPLETED
-
Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients
NCT07250217 ·Status: RECRUITING ·Phase: NA
-
Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors
NCT02519712 ·Status: TERMINATED ·Phase: NA
-
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
NCT02927938 ·Status: TERMINATED ·Phase: PHASE3
-
Membrane Target Detection for Leukemia Treatment
NCT04841447 ·Status: RECRUITING
-
AML-MDS Novel Prognostic Tests Clinical Study
NCT01685619 ·Status: COMPLETED
-
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562 ·Status: RECRUITING ·Phase: PHASE3
-
Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)
NCT02662920 ·Status: COMPLETED
-
Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant
NCT03921047 ·Status: RECRUITING
-
Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission
NCT02587871 ·Status: WITHDRAWN ·Phase: PHASE2
-
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
NCT00687323 ·Status: COMPLETED ·Phase: PHASE2